Skip to main content
. 2022 Jan;40(1):10–38. doi: 10.2337/cd22-as01

TABLE 9.2.

Drug-Specific and Patient Factors to Consider When Selecting Antihyperglycemic Treatment in Adults With Type 2 Diabetes

graphic file with name diaclincd22as01t1.jpg

*

For agent-specific dosing recommendations, please refer to the manufacturers’ prescribing information.

†

FDA-approved for CVD benefit.

‡

FDA-approved for HF indication.

§

FDA-approved for CKD indication. CVOT, cardiovascular outcomes trial; DPP-4, dipeptidyl peptidase 4; GLP-1 RA, glucagon-like peptide 1 receptor agonist; NASH, nonalcoholic steatohepatitis; SQ, subcutaneous; T2D, type 2 diabetes.